论文部分内容阅读
目的探讨雌二醇/孕激素联合方案对人乳腺癌细胞MCF-7和MCF-7/PGRMC1(WT-12)增殖的影响。方法 MCF-7细胞,用表达PGRMC1的质粒稳定转染到MCF-7细胞,使其成为MCF-7/WT-12乳腺癌细胞。雌二醇浓度(10-10M,10-12M,10-14M)与孕酮、合成孕激素安宫黄体酮、炔诺酮序贯联合加入上述两种人乳腺癌细胞进行培养6天,MTT法分别测定MCF-7、MCF-7/WT-12肿瘤细胞的生长增殖情况。结果单纯雌二醇在高浓度10-10M下,明显刺激细胞生长,这种生长不受加入各种孕激素的影响。单纯雌二醇在低浓度下10-12M、10-14M下对MCF-7及MCF-7/WT-12细胞刺激增殖作用轻微或没有明显刺激细胞增殖的作用,然而,加用炔诺酮则可激发细胞明显的增殖反应,而增加安宫黄体酮和孕酮则显示中性作用,无激发反应。MCF-7/WT-12细胞的增殖反应更明显。结论雌二醇在表达孕激素受体膜组分1(progesterone receptor membrane component 1,PGRMC1)的MCF-7细胞中能明显诱发细胞增殖的增加,且表现为剂量依赖性。在低的雌二醇浓度下,某些孕激素可能启动了一种强增殖信号。关于HRT低剂量雌二醇致乳腺癌风险增加的可能性,可能与用某些特殊的孕激素有关。
Objective To investigate the effect of estradiol / progestin combination on the proliferation of human breast cancer cells MCF-7 and MCF-7 / PGRMC1 (WT-12). Methods MCF-7 cells were stably transfected into MCF-7 cells with the plasmid expressing PGRMC1 to make MCF-7 / WT-12 breast cancer cells. Estradiol concentration (10-10M, 10-12M, 10-14M) and progesterone, progesterone progesterone synthesis progesterone, norethindrone were added to the above two human breast cancer cells cultured for 6 days, MTT method The growth and proliferation of MCF-7, MCF-7 / WT-12 tumor cells were measured respectively. Results The estradiol significantly stimulated the cell growth under high concentration of 10-10M, which was not affected by the addition of various progestins. Pure estradiol had little or no effect on cell proliferation stimulated by MCF-7 and MCF-7 / WT-12 cells at low concentration of 10-12M and 10-14M, however, norethindrone Can stimulate the cell proliferation reaction significantly, and increase the progesterone and progesterone progesterone showed a neutral effect, no excitation response. The proliferative response of MCF-7 / WT-12 cells was more obvious. Conclusion Estradiol significantly induced cell proliferation in MCF-7 cells expressing progesterone receptor membrane component 1 (PGRMC1) in a dose-dependent manner. At low estradiol concentrations, some progestins may initiate a strong proliferative signal. The possibility of an increased risk of breast cancer with low-dose HRT of estradiol may be related to the use of some specific progestins.